Sponsor
Pfizer Australia
121 PBAC submissions on file, active 2005–2025. 75% have been recommended.
Submissions
121
2005 → 2025
Win rate
75 %
90 recommended of 120 bucketable
Drugs
62 · 50 listed
unique molecules submitted
PBS spend captured
$84M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Oncology 34 Rheumatology 14 Vaccines 11 Haematology 9 Cardiovascular 7 Endocrinology 7 Neurology 6 Infectious disease 5 Other 5 Dermatology 4
Activity by year 2005 (5) · 2006 (5) · 2007 (3) · 2008 (7) · 2009 (2) · 2010 (2) · 2011 (3) · 2012 (6) · 2013 (4) · 2014 (7) · 2015 (4) · 2016 (6) · 2017 (5) · 2018 (13) · 2019 (9) · 2020 (6) · 2021 (11) · 2022 (3) · 2023 (6) · 2024 (10) · 2025 (4)
Rejection patterns
Across 18 Not recommended decisions on file.
2× unacceptably high and uncertain ICER1× inadequate data to support claim of superior clinical effectiveness over best supportive care1× indirect comparison not informative due to significant risk of bias in RENCOMP study1× substantial differences in study design and baseline characteristics1× progression free survival not adequately supported as surrogate for overall survivalOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.